semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Relapsing-Remitting Multiple Sclerosis Aged 18 to 55 years old Presence of myelin reactive T cells at screening Diagnosis of CIS with screening MRI that fulfils the Barkhof dissemination in space Diagnosis of MS within the past 10 years according to the McDonald (2005) Baseline EDSS score between 0 and 5.5 inclusively  Unable to produce T cell vaccine Disease-modifying treatment for MS during the last 30 days and 60 days for steroidal treatments Diagnosis of progressive-relapsing, secondary progressive, or primary progressive MS Planned pregnancy, currently pregnant, or breastfeeding Any prior treatment with total lymphoid irradiation, cladribine, T cell or T cell receptor vaccination
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis age 18-55 Relapsing-Remitting Multiple Sclerosis (RRMS) Avonex therapy for 6 months prior continuous annualized relapse rate >2 during Avonex therapy most recent relapse within 60 days of baseline entry Expanded Disability Status Scale (EDSS) 1.5-4.5 one or more gadolinium (Gd+) MRI lesions on a baseline MRI no history of immune modulator or immunosuppressant therapy used in combination with Avonex (other then GSC administer for clinical relapses) not participating in any other study of ms therapeutics Serum neutralizing antibodies (NABs) titer to Avonex <20  Medical or Psychiatric conditions that will affect patients ability to provide informed consent inability to undergo MRI clinically serious medical conditions or significantly abnormal labs no use of these medications or procedures within six months prior to study: *monoclonal antibodies,total lymphoid radiation,systemic steroids,cytotoxic or immunosuppressive medications such as mitoxantrone or cyclophosphamide or any other investigational drugs Interferon neutralizing antibody titers >20 no breast feeding or pregnant no patients with any systemic illness,psychiatric condition or other disorder that would concern safety of patient to complete procedures of protocol abnormal blood test clinically significant abnormality on chest x-ray (CXR)
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Multiple Sclerosis MS patients according to Poser's Remitting evolution (less than two years of evolution) Aged 18-50 Immunomodulatory treatment indicated  Unable to perform MRI
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Relapsing-remitting Multiple Sclerosis Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis Patients with a relapsing-remitting disease course Patients with EDSS score of 0-5.5  Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc Pregnant or nursing women Other protocol-defined inclusion/ applied to this study
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 13.0-65.0,  Pneumonia, Interstitial Plasma Cell Pneumocystis Carinii Pneumonia Pneumonia, Pneumocystis Carinii HIV Infections Documented or presumptive HIV infection Signs and symptoms of PCP present for at least 5 days Pneumocystis jiroveci confirmed in BAL fluid or induced sputum sample Suitable candidate for oral therapy Alveolar-arterial oxygen (A-a) gradient < or = 45 mm Hg on room air and partial pressure of oxygen (pO2) > or = 60 mm Hg No more than 48 hours of prior treatment in the preceding 7 days for PCP treatment at full doses; failure of Pneumocystis prophylaxis or use of medications recommended for treatment of PCP at doses less than recommended by the CDC Guidelines is acceptable  Unwilling or unable to discontinue use of other medications with anti-PCP activity AIDS related cachexia (weight loss that is more than 10% of ideal body weight) Severe diarrhea and/or vomiting History of hypersensitivity or severe or life threatening toxicity to TMP-SMX, other sulfonamides or pentamidine Active illicit drug use Impending respiratory failure or need for intubation AST and ALT levels > 3 times the upper limit of normal History of pancreatitis Severe PCP Karnofsky score < or = 20
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Multiple Sclerosis Clinical diagnosis of multiple sclerosis EDSS less than 5.5 No cognitive disability  EDSS over 5.5 Inability to cooperate with gait analysis
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  ALS Cases were eligible to participate in the original study if (1) they had received a diagnosis of ALS within 2 years; (2) they lived in New England at least half the year; (3) they spoke English; (4) they were mentally and physically able to participate. The same were used for controls  Potential controls were excluded if they had a physician diagnosis of a neurodegenerative disease, polio, post-polio syndrome, or nondiabetic neuropathy. Pregnant women were excluded from both case and control groups
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis (MS) Patients with a relapsing-remitting disease course Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5  Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc Pregnant or nursing women Patients who cannot tolerate treatment with an interferon Other protocol-defined inclusion/ applied to the study
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Amyotrophic Lateral Sclerosis ALS Participants will be people with ALS, at least 18 years of age Participants must be medically able to undergo the study procedures and have a caregiver or other individual who will be available to help with daily study medication administration Participants should live within a reasonable distance of the study site, due to frequent study visits  Participants cannot be taking any other experimental medications for ALS, or have a history of sensitivity to cephalosporin antibiotics (such as Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax, or Fortaz)
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis Patients with a relapsing-remitting disease course Patients with expanded disability status scale (EDSS) score of 0-5.5  Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc Pregnant or nursing women For in the extension phase patients should complete the 24 month core study with or without 24 months on study drug. If a patient discontinued study drug during the core study due to an adverse event, serious adverse event, laboratory abnormality etc. they would be excluded from the Extension Phase. Other protocol-defined inclusion/
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Relapsing-Remitting Multiple Sclerosis A patient may be included if he/she Is aged between 18 and 55 years (both included) Has multiple sclerosis according to the McDonald (McDonald 2001) Has a stable disease during the last month period prior to and a disability equivalent to EDSS of 5.5 or less (Kurtzke 1983) Has shown disease activity defined as at least one relapse or at least one new MRI lesion (T1 enhancing or T2 lesion ref. McDonald criteria) during the year prior to inclusion Is prepared to and considered able to follow the protocol and to attend the planned visits during the whole study period Is using adequate contraceptive methods and has negative pregnancy test results (female of childbearing potential must) Has given written informed consent  A patient has to be excluded if he/she Has received continuous for more than one-week treatment with unsaturated fatty acids (omega-3) within 3 months prior to in the study Has an active RRMS disease that would strongly be recommended for standard immunomodulatory treatment by the treating neurologist Has received treatment with interferon-beta or glatiramer acetate within 6 months prior to in the study Has received treatment with lymphoid irradiation, mitoxantrone, cyclophosphamide or long-term glucocorticoids Has received treatment with azathioprine, cyclosporine or other immunosuppressive agents within the year prior to in the study Has received treatment with glucocorticoids or ACTH within two month prior to in the study Has experienced a relapse within one month prior to the in the study Has converted to secondary progressive MS Has suffered from major depression or any other psychiatric disorder that would preclude safe participation in the protocol
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Relapsing Remitting Multiple Sclerosis Definite diagnosis of multiple sclerosis by the McDonald criteria. 2. Screening cranial MRI demonstrating lesions consistent with MS. 3. One or more relapses within the previous year. 4. Clinically stable (no relapses) for > 50 days before beginning screening procedures and during the screening period. 5. EDSS 0 to 3.5 inclusive. 6. Age > 17 years and < 56 years. 7. Willing and able to give informed consent. 8. WBC >3,000; platelets >100,000; hemoglobin > 10.0 g/dl. 9. AST, ALT, bilirubin < 2.0 x upper limit of normal. 10. Creatinine < 2.0 x upper limit of normal. 11. Negative test for HIV  Primary progressive, secondary progressive or progressive relapsing MS. 2. More than 5 gadolinium-enhancing lesions on the first screening MRI. 3. High-dose corticosteroids (e.g. > 500 mg methylprednisolone or equivalent per day for 3 or more days) within 50 days prior to beginning screening procedures. 4. Previous stem cell transplantation, total lymphoid radiation, or cytotoxic therapy. 5. Treatment with interferon, glatiramer acetate or other approved disease-modifying agent for > 180 days (lifetime total of all agents). 6. Treatment with an approved disease modifying agent within 180 days of beginning screening procedures. 7. Previous treatment of MS with an experimental agent including off-label use of approved drugs. (Allowed with approval of the Medical Monitor.) 8. Prior therapy with natalizumab (Tysabri). 9. Pregnant or lactating women. 10. Unwilling to use a medically acceptable form of birth control (e.g. hormonal contraception, intrauterine device, double barriers, sterilization of self or partner). 11. Clinically significant ECG abnormalities (e.g. acute ischemia or life-threatening arrhythmia). 12. Medical condition or social circumstances that would in the opinion of the investigator prevent full participation in the trial or evaluation of study endpoints. 13. Implanted pace makers, defibrillators or other metallic objects on or inside the body that limit performing MRI scans. 14. Known hypersensitivity or allergy to gadolinium